Efficacy and Safety of Rezum System Water Vapor Treatment for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F15%3A00084914" target="_blank" >RIV/00216224:14110/15:00084914 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/65269705:_____/15:00063563

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.urology.2015.05.046" target="_blank" >http://dx.doi.org/10.1016/j.urology.2015.05.046</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.urology.2015.05.046" target="_blank" >10.1016/j.urology.2015.05.046</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Efficacy and Safety of Rezum System Water Vapor Treatment for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia

Popis výsledku v původním jazyce

To assess 1-year efficacy and safety data from pilot trials of the Rezum System water vapor to treat lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). A total of 65 men with symptoms of moderate to severe BPH were enrolled in pilot studies at centers in the Dominican Republic, the Czech Republic, and Sweden. Each patient was treated with transurethral delivery of sterile water vapor (steam). International Prostate Symptom Score (1PSS), peak urinary flow (Qmax), qualityof life (QoL), postvoid residual, International Index of Erectile Function, and prostate-specific antigen were evaluated at 1 week and 1, 3, 6, and 12 months post-treatment. Safety was also assessed. Statistically significant clinical improvements at 1,3, 6, and 12 months were reported for IPSS (decreased by 6.8, 13.4, 13.1, and 12.5 points, respectively) and Qmax (increased by 2.0, 4.7, 4-3, and 4-6 mL/sec, respectively). At 12 months, these results equated to a 56% improvement in IPSS

Název v anglickém jazyce

Efficacy and Safety of Rezum System Water Vapor Treatment for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia

Popis výsledku anglicky

To assess 1-year efficacy and safety data from pilot trials of the Rezum System water vapor to treat lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). A total of 65 men with symptoms of moderate to severe BPH were enrolled in pilot studies at centers in the Dominican Republic, the Czech Republic, and Sweden. Each patient was treated with transurethral delivery of sterile water vapor (steam). International Prostate Symptom Score (1PSS), peak urinary flow (Qmax), qualityof life (QoL), postvoid residual, International Index of Erectile Function, and prostate-specific antigen were evaluated at 1 week and 1, 3, 6, and 12 months post-treatment. Safety was also assessed. Statistically significant clinical improvements at 1,3, 6, and 12 months were reported for IPSS (decreased by 6.8, 13.4, 13.1, and 12.5 points, respectively) and Qmax (increased by 2.0, 4.7, 4-3, and 4-6 mL/sec, respectively). At 12 months, these results equated to a 56% improvement in IPSS

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FP - Ostatní lékařské obory

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Urology

ISSN

0090-4295

e-ISSN

—

Svazek periodika

86

Číslo periodika v rámci svazku

5

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

6

Strana od-do

1042-1047

Kód UT WoS článku

000366466400049

EID výsledku v databázi Scopus

—